



EPICS

BREAST CANCER IN 2020 AND BEYOND

Part 1: EPICS May 11 – HER2+ Breast Cancer

Part 2: EPICS May 18 – TNBC and HR+ Breast Cancer

Part 3: OncoBoard Online Discussion Platform

FACULTY EXPERTS



Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center
University of Pittsburgh MC



Jame Abraham, MD, FACP
Cleveland Clinic, Cleveland



William Gradishar, MD
Northwestern Medicine,
Chicago



Monica Fornier, MD
Memorial Sloan Kettering Cancer
Center, New York



Peter Kaufman, MD
University of Vermont Cancer
Center, Burlington



Virginia Kaklamani, MD
UT Health San Antonio, MD
Anderson Cancer Center



Rita Nanda, MD
University of Chicago
Hematology Oncology



Mark D. Pegram, MD
Stanford University School of
Medicine, Palo Alto



Hope Rugo, MD
UCSF Helen Diller Family
Comprehensive Cancer Center,
San Francisco



Jasjit Sachdev, MD
HonorHealth Research Institute,
Scottsdale

Topic	Speaker/Moderator
Welcome and Introductions	Adam Brufsky, MD, PhD
New Standards in HER2+ Early Breast Cancer	Jame Abraham, MD, FACP
Key Questions and Topics for Discussion	All
Key Takeaways HER2+ Early Breast Cancer	Adam Brufsky, MD, PhD
Maximizing Potential in HER2+ mBC	Mark Pegram, MD
Key Questions and Topics for Discussion	All
Key Takeaways HER2+ mBC	Adam Brufsky, MD, PhD
Wrap-up and Overview	Adam Brufsky, MD, PhD

KEY UPDATES ON NEOADJUVANT AND ADJUVANT THERAPY FOR HER2+ BREAST CANCER (JAME ABRAHAM)

> Neoadjuvant setting

[The content of this slide is heavily blurred and illegible.]

KEY UPDATES ON NEOADJUVANT AND ADJUVANT THERAPY FOR HER2+ BREAST CANCER (JAME ABRAHAM)

> Future trials to watch in the postneoadjuvant setting for patients with residual

[This section contains blurred text, likely representing a list of clinical trials or research updates.]

KEY TAKEAWAYS PART 1: NEOADJUVANT AND ADJUVANT THERAPY FOR HER2+ BREAST CANCER (1/3)

> Human epidermal growth factor receptor 2 (HER2)+ neoadjuvant setting: what is

[This section contains blurred text, likely representing a list of key takeaways or a detailed discussion of the neoadjuvant setting for HER2+ breast cancer.]

KEY TAKEAWAYS PART 1: NEOADJUVANT AND ADJUVANT THERAPY FOR HER2+ BREAST CANCER (2/3)

> Adjuvant setting

[The content of this slide is intentionally blurred for privacy or security reasons.]

KEY TAKEAWAYS PART 1: NEOADJUVANT AND ADJUVANT THERAPY FOR HER2+ BREAST CANCER (3/3)

> Adjuvant setting (cont'd)

[The content of this slide is intentionally blurred for privacy or security reasons.]

KEY UPDATES ON HER2+ METASTATIC BREAST CANCER

(MARK PEGRAM)

> HER2CLIMB (capecitabine, trastuzumab, ± tucatinib) met statistical significance at the first planned

KEY TAKEAWAYS PART 2: INTRODUCTION HER2+ METASTATIC BREAST CANCER

> Despite the overwhelming response data for trastuzumab in NSABP B-31 back in

[The following text is heavily blurred and illegible.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (1/6)

> The experts all agree that tucatinib and DS-8201 (trastuzumab deruxtecan

[The following text is heavily blurred and illegible.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (2/6)

> Experts are excited about the recent US Food and Drug Administration (FDA)

[The following text is heavily blurred and illegible.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (3/6)

> Most of the experts are currently confident to administer tucatinib as primary

[This section contains blurred text, likely representing a list of key takeaways or discussion points.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (4/6)

> HER2+/hormone receptor-positive (HR+), triple-positive patients

[This section contains blurred text, likely representing a list of key takeaways or discussion points.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (5/6)

> New molecules

[The content of this slide is intentionally blurred for privacy or confidentiality.]

KEY TAKEAWAYS PART 2: DISCUSSION HER2+ METASTATIC BREAST CANCER (6/6)

> Biosimilars

[The content of this slide is heavily blurred and illegible.]



EPICS

BREAST CANCER IN 2020 AND BEYOND

Monday, May 18, 2020

Topic	Speaker/Moderator
Welcome and Introductions	Adam Brufsky, MD, PhD
Current and Investigational Approaches in Triple-Negative Breast Cancer	Rita Nanda, MD
Key Questions and Topics for Discussion	All
Key Takeaways Triple-Negative Breast Cancer	Adam Brufsky, MD, PhD
Evolving Treatments and New Developments in HR+ Metastatic Breast Cancer	Hope Rugo, MD
Key Questions and Topics for Discussion	All
Key Takeaways HR+ Metastatic Breast Cancer	Adam Brufsky, MD, PhD
New Standards in HR+ Early Breast Cancer	Virginia Kaklamani, MD
Key Questions and Topics for Discussion	All
Key Takeaways HR+ Early Breast Cancer	Adam Brufsky, MD, PhD
Wrap-up and Overview	Adam Brufsky, MD, PhD

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – OVERVIEW (1/2)

> While sequential lines of chemotherapy remain the mainstay of TNBC treatment, recent approvals

[The following text is heavily blurred and illegible. It appears to be a list of bullet points or a detailed paragraph discussing TNBC treatment options, including mentions of immunotherapy and targeted therapies.]

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – OVERVIEW (2/2)

> Ongoing research with new actionable targets and/or novel combinations (cont'd)

[This section contains blurred text, likely representing a list of research topics or clinical trial details.]

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – DISCUSSION HIGHLIGHTS (1/5)

Biomarker testing

[Blurred content area]

*Patients <60 years, family history of prior breast or ovarian cancer, and/or other predispositions.

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – DISCUSSION HIGHLIGHTS (2/5)

Biomarker testing (cont'd)

[The content of this section is intentionally blurred for privacy and confidentiality.]

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – DISCUSSION HIGHLIGHTS (3/5)

PARP inhibitors and checkpoint inhibitors – metastatic setting

[The following text is intentionally blurred for privacy and readability.]

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – DISCUSSION HIGHLIGHTS (4/5)

PARP inhibitors and checkpoint inhibitors – metastatic setting (cont'd)

[The content of this section is heavily blurred and illegible.]

TRIPLE-NEGATIVE BREAST CANCER (TNBC) – DISCUSSION HIGHLIGHTS (5/5)

ADCs

[The following text is intentionally blurred for privacy and readability.]

- > Remarkable progress has led to changing paradigms in the treatment of HR+, HER2– mBC

Recent advances in HR+ mBC

[The content of this slide is intentionally blurred for privacy.]

HR+ METASTATIC BREAST CANCER – DISCUSSION HIGHLIGHTS (1/3)

> CDK4/6 inhibitors have become the default first-line treatment for the majority of patients with

HR+ METASTATIC BREAST CANCER – DISCUSSION HIGHLIGHTS (2/3)

> Safety and complexity of management (eg, need for electrocardiogram with ribociclib) are other

HR+ METASTATIC BREAST CANCER – DISCUSSION HIGHLIGHTS (3/3)

> Upon progression on CDK4/6 inhibitors, current treatment decision depends on *PI3K* status, which is

[The following text is heavily blurred and illegible. It appears to be a list of options or a detailed discussion of treatment strategies based on PI3K status.]

Neoadjuvant ET

[The content of this slide is intentionally blurred for privacy.]

Adjuvant ET

[The content of this slide is intentionally blurred for privacy.]

> Experts are very intrigued by neoadjuvant ET as an alternative option to neoadjuvant



EPICS

BREAST CANCER IN 2020 AND BEYOND

OncoBoard

Q1. WILL THERE BE ANY LONG-TERM IMPACTS OF COVID-19 ON YOUR BREAST CANCER PRACTICE AND THE WAY YOU SEE PATIENTS? IF SO, WHAT ARE 3 MAJOR EXPECTED CHANGES FOR YOUR PRACTICE IN THE FUTURE? (1/3)

> Overall, the experts believe that in the coming months, their practices will return to

[Blurred content]

Q1. WILL THERE BE ANY LONG-TERM IMPACTS OF COVID-19 ON YOUR BREAST CANCER PRACTICE AND THE WAY YOU SEE PATIENTS? IF SO, WHAT ARE 3 MAJOR EXPECTED CHANGES FOR YOUR PRACTICE IN THE FUTURE? (2/3)

> **Telemedicine:** the experts believe telemedicine will remain after COVID-19 in

Q1. WILL THERE BE ANY LONG-TERM IMPACTS OF COVID-19 ON YOUR BREAST CANCER PRACTICE AND THE WAY YOU SEE PATIENTS? IF SO, WHAT ARE 3 MAJOR EXPECTED CHANGES FOR YOUR PRACTICE IN THE FUTURE? (3/3)


> Drug regimens and formulations

- 1. [Blurred text]
- 2. [Blurred text]
- 3. [Blurred text]
- 4. [Blurred text]
- 5. [Blurred text]
- 6. [Blurred text]
- 7. [Blurred text]
- 8. [Blurred text]
- 9. [Blurred text]
- 10. [Blurred text]
- 11. [Blurred text]
- 12. [Blurred text]
- 13. [Blurred text]
- 14. [Blurred text]
- 15. [Blurred text]
- 16. [Blurred text]
- 17. [Blurred text]
- 18. [Blurred text]
- 19. [Blurred text]
- 20. [Blurred text]
- 21. [Blurred text]
- 22. [Blurred text]
- 23. [Blurred text]
- 24. [Blurred text]
- 25. [Blurred text]
- 26. [Blurred text]
- 27. [Blurred text]
- 28. [Blurred text]
- 29. [Blurred text]
- 30. [Blurred text]
- 31. [Blurred text]
- 32. [Blurred text]
- 33. [Blurred text]
- 34. [Blurred text]
- 35. [Blurred text]
- 36. [Blurred text]
- 37. [Blurred text]
- 38. [Blurred text]
- 39. [Blurred text]
- 40. [Blurred text]
- 41. [Blurred text]
- 42. [Blurred text]
- 43. [Blurred text]
- 44. [Blurred text]
- 45. [Blurred text]
- 46. [Blurred text]
- 47. [Blurred text]
- 48. [Blurred text]
- 49. [Blurred text]
- 50. [Blurred text]
- 51. [Blurred text]
- 52. [Blurred text]
- 53. [Blurred text]
- 54. [Blurred text]
- 55. [Blurred text]
- 56. [Blurred text]
- 57. [Blurred text]
- 58. [Blurred text]
- 59. [Blurred text]
- 60. [Blurred text]
- 61. [Blurred text]
- 62. [Blurred text]
- 63. [Blurred text]
- 64. [Blurred text]
- 65. [Blurred text]
- 66. [Blurred text]
- 67. [Blurred text]
- 68. [Blurred text]
- 69. [Blurred text]
- 70. [Blurred text]
- 71. [Blurred text]
- 72. [Blurred text]
- 73. [Blurred text]
- 74. [Blurred text]
- 75. [Blurred text]
- 76. [Blurred text]
- 77. [Blurred text]
- 78. [Blurred text]
- 79. [Blurred text]
- 80. [Blurred text]
- 81. [Blurred text]
- 82. [Blurred text]
- 83. [Blurred text]
- 84. [Blurred text]
- 85. [Blurred text]
- 86. [Blurred text]
- 87. [Blurred text]
- 88. [Blurred text]
- 89. [Blurred text]
- 90. [Blurred text]
- 91. [Blurred text]
- 92. [Blurred text]
- 93. [Blurred text]
- 94. [Blurred text]
- 95. [Blurred text]
- 96. [Blurred text]
- 97. [Blurred text]
- 98. [Blurred text]
- 99. [Blurred text]
- 100. [Blurred text]



Q2. DO YOU MANAGE ADVERSE EVENTS DIFFERENTLY IN THE CONTEXT OF THE COVID-19 PANDEMIC? DO YOU NOTICE A DIFFERENCE IN AE MANAGEMENT BETWEEN UNIVERSITY AND COMMUNITY HOSPITALS? CAN YOU PRACTICALLY ILLUSTRATE YOUR APPROACH FOR SOME NEWER DRUGS (EG, T-DM1, TUCATINIB, TRASTUZUMAB DERUXTECAN)?

> The majority of physicians mentioned there are no changes at all in their



Q3. HOW DOES USE OF HER2-TARGETED REGIMENS IN THE (NEO)ADJUVANT SETTING IMPACT YOUR TREATMENT SELECTION WHEN METASTATIC DISEASE DEVELOPS, AND HOW IS THIS EVOLVING? PLEASE CLARIFY WITH A FEW EXAMPLES OF AGENTS THAT COULD BE AFFECTED.

> The experts guide their treatment decision by DFI on a previous regimen. If this is

Q4. WHERE DO YOU SEE THE FUTURE OF IMMUNOTHERAPY IN BREAST CANCER (NOT INCLUDING ADCS)? PLEASE SPECIFY DISEASE SETTINGS AND PROMISING AGENTS, PATHWAYS, AND HYPOTHESES. (1/2)

> The experts feel there is a clear place for immunotherapy in TNBC

[Blurred content]

Q4. WHERE DO YOU SEE THE FUTURE OF IMMUNOTHERAPY IN BREAST CANCER (NOT INCLUDING ADCS)? PLEASE SPECIFY DISEASE SETTINGS AND PROMISING AGENTS, PATHWAYS, AND HYPOTHESES. (2/2)

> Experts believe that a subset of patients may be identified who can do well with

[Blurred content]

Q5. HOW DO YOU SEE ADCS EVOLVING WITHIN THE BREAST CANCER SPACE OVER THE NEXT 5 YEARS? IN HER2+ DISEASE? IN HER2- DISEASE? IN LATE-STAGE OR EARLY DISEASE?

> The experts are excited about ADCs: “This is the decade of the ADCs.” They expect ADCs

Q6. WHAT ARE THE MOST PROMISING NOVEL TARGETS BEYOND CDK? WHERE DO YOU ENVISION PI3K, AURKA, OR MTOR INHIBITORS FITTING INTO THE EVOLVING TREATMENT ALGORITHM? WHAT ABOUT MEK, AKT, FGFR, BCL2?

> AKT inhibitors are considered the most interesting new targeted therapies by the experts.

Q7. WHERE DO YOU SEE THE GREATEST POTENTIAL FOR ORAL SERDS? WHICH UNMET NEED COULD THESE DRUGS FILL? WHAT WOULD BE A GOOD DISEASE SETTING?

> Oral SERDS are considered attractive by all the experts, if efficacy and safety are



EPICS

IMPACT OF COVID-19: HIGHLIGHTS

> Overall, the experts believe that in the coming months, their practices will return to

- The majority of respondents expect their practices to return to pre-pandemic levels within the next 6-12 months.
- However, a significant portion of respondents expect their practices to remain at a level below pre-pandemic levels for an extended period.
- The impact of COVID-19 on the healthcare industry is expected to be long-lasting, with many practices adopting new technologies and workflows.
- The healthcare industry is expected to continue to evolve, with a focus on digital health and patient engagement.

IMPACT OF COVID-19: TELEMEDICINE



> The advisors expect that telemedicine will remain after COVID-19 in specific

- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]
- [blurred text]

IMPACT OF COVID-19: DRUG REGIMENS AND FORMULATIONS (1/2)

> Drug regimens are being critically assessed in the current situation, and experts

[The following text is heavily blurred and illegible.]

IMPACT OF COVID-19: DRUG REGIMENS AND FORMULATIONS (2/2)

> For hormone receptor (HR)+ patients, experts indicated that during the peak of the

[Blurred text area]

> COVID-19 also impacted the execution of clinical trials, and several have been

 A large, dark blue, stylized logo consisting of several thick, curved lines that form a circular, sunburst-like shape. The lines are thick and have a slight taper at the ends, creating a sense of movement and energy.

EPICS

Strategic Considerations: General

> COVID-19 has accelerated the integration of telemedicine into patient care, as a

> Oral selective estrogen receptor downregulators/degraders (SERDs) are eagerly

[The following text is heavily blurred and illegible.]